Pfizer (PFE) Tops Q2 EPS by 14c; raises guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Pfizer (PFE) PT Raised to $34 at Goldman Sachs
July 31, 2024 5:20 AM EDTGoldman Sachs analyst Chris Shibutani raised the price target on Pfizer (NYSE: PFE) to $34.00 (from $31.00) while maintaining a Buy rating.
The analyst comments "Relative outperformance on the day (+2% vs. flat XLV) appears warranted in our view given solid 2Q results... More
Pfizer hikes full-year outlook as Q2 results top estimates; shares up
July 30, 2024 6:58 AM EDT(Updated - July 30, 2024 9:48 AM EDT)
Pfizer (NYSE: PFE) shares rose more than 1% at the start of trading on Tuesday after the drugmaker hiked full-year guidance and reported better-than-expected Q2 earnings and revenue.
The companys earnings per share (EPS) in the second quarter stood at $0.60, surpassing the consensus estimate of $0.46. Revenue came in at $13.3 billion, also above the projected $13.03 billion.
Pfizer reported adjusted research and development expenses of $2.67 billion for the... More
